What is Scinai?
Scinai Immunotherapeutics operates at the intersection of advanced immunology and biopharmaceutical manufacturing. The company specializes in the development and commercialization of innovative biological products designed to address significant unmet medical needs in the autoimmune and infectious disease sectors. Central to its value proposition is a state-of-the-art facility that provides end-to-end boutique CDMO services, allowing the firm to maintain operational agility while simultaneously progressing its own nanosized VHH antibody (NanoAb) pipeline.
By integrating internal R&D with external manufacturing partnerships, Scinai effectively mitigates the risks typically associated with early-stage drug development. This hybrid approach, supported by a leadership team with deep pharmaceutical industry expertise, positions the company as a versatile player capable of navigating the complex regulatory and technical requirements of modern immunology.
How much funding has Scinai raised?
Scinai has raised a total of $2.6M across 1 funding round:
Stock/Share Issuance
$2.6M
Stock/Share Issuance (2026): $2.6M, investors not publicly disclosed
Key Investors in Scinai
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Scinai?
Looking ahead, the strategic deployment of the $2.6M will likely focus on scaling the company's CDMO infrastructure and accelerating the clinical progression of its NanoAb platform. As the firm transitions into a more mature phase of its lifecycle, the focus will shift toward optimizing manufacturing efficiencies and securing potential licensing agreements for its proprietary assets. The company's ability to maintain its boutique service model while scaling production will be a critical factor in its long-term growth trajectory. Investors will be closely monitoring the firm's progress in translating its innovative antibody research into tangible clinical outcomes, which remains the primary driver for long-term shareholder value in the biopharmaceutical sector.
See full Scinai company page
